First Wave BioPharma to Present at the BIO CEO & Investor Conference

Rhea-AI Summary

First Wave BioPharma (NASDAQ: FWBI) announced that James Sapirstein, Chairman, President, and CEO, will present at the BIO CEO & Investor Conference on February 6, 2023, at the Marriott Marquis in New York City. The presentation is scheduled for 9:30 a.m. EST in the Winter Garden Room. The management team will hold one-on-one meetings with investors to discuss the company's business strategy, recent achievements, and future milestones. First Wave develops targeted therapies for gastrointestinal diseases, with ongoing clinical programs for conditions like exocrine pancreatic insufficiency and ulcerative colitis.

BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.

Details of the presentation are as follows: 

Event:	BIO CEO & Investor Conference
Date:	Monday, February 6, 2023
Time:	9:30 a.m., EST
Location:	Winter Garden Room, Marriott Marquis, New York City

During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

About First Wave BioPharma, Inc.
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical-stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

Forward-Looking Statement
This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the contemplated offering will be successful and whether the Company will be able to regain and maintain compliance with Nasdaq’s continued listing criteria; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@firstwavebio.com

Media contact:
Tiberend Strategic Advisors, Inc.
David Schemelia
(609) 468-9325
dschemelia@tiberend.com

Bill Borden
(732) 910-1620
bborden@tiberend.com

FAQ

What date is the BIO CEO & Investor Conference where FWBI will present?

The BIO CEO & Investor Conference will take place on February 6, 2023.

What time will FWBI's presentation occur during the conference?

FWBI's presentation is scheduled for 9:30 a.m. EST.

Where is the BIO CEO & Investor Conference being held?

The conference is being held at the Marriott Marquis in New York City.

What is First Wave BioPharma's focus area?

First Wave BioPharma specializes in developing targeted therapies for gastrointestinal diseases.

What are some clinical programs First Wave BioPharma is involved in?

First Wave is advancing programs for exocrine pancreatic insufficiency, ulcerative colitis, and Crohn's disease.